EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST

04.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CEST The issuer is solely responsible ...

Related Keywords

Italy , Germany , Boston , Massachusetts , United States , Berlin , Lugano , Italy General , Planegg , Bayern , Canada , Frankfurt , Brandenburg , Hanover , Niedersachsen , Munich , Hamburg , German , Italian , American , Julia Neugebauer , Eamonn Nolan , Tim Demuth , Thomas Biegi , Distribution Services , Tradegate Exchange , Linkedin , News Service , Constellation Pharmaceuticals Inc , Twitter , Nasdaq , American Society Of Hematology , Xencor Inc , Us Oncology Network , Exchange Commission , Drug Administration , German Lymphoma Association , Sys Completes Enrollment , Topline Results Expected , Chief Research , Development Officer , Myelofibrosis Symptom Assessment Form , American Society , Constellation Pharmaceuticals , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide , Prescribing Information , Patient Information , Important Safety , Diffuse Largeb Cell Lymphoma , Italian Lymphoma , Blinded Independent Review Committee , Morphosy Annual Report , Corporate News , Regulatory Announcements , Prime Standard , Regulated Unofficial Market , Morphosys , Qs News ,